None
Conditions
Interventions
Teglitide Group:After the procedure, 1 mg of Ticagrelor was administered intravenously
Sufentanil Group:After the procedure, 5 µg of sufentanil was administered intravenously.
Sponsors
The First Affiliated Hospital of Anhui University of Science and Technology
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Age 18–60 years; (2) BMI 18.5–27.9 kg/m²; (3) ASA classification I–II; (4) No preoperative respiratory diseases and normal airway assessment
Exclusion criteria
Exclusion criteria: (1) Decompensation of major organs; (2) Long-term use of opioids, analgesics, sedatives, or a history of alcohol abuse; (3) Allergy to drugs used in this study, such as ticagrelor or sufentanil; (4) Pregnancy or breastfeeding; (5) Language barriers or inability to cooperate; (6) Withdrawal from this trial midway.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative recovery quality;Postoperative pain; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recovery time;Postoperative adverse reactions;Depth of sedation; | — |
Countries
China
Contacts
Public ContactShi Jun
The First Affiliated Hospital of Anhui University of Science and Technology
Outcome results
None listed